X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs IPCA LABS - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA IPCA LABS AUROBINDO PHARMA/
IPCA LABS
 
P/E (TTM) x 14.3 41.9 34.2% View Chart
P/BV x 3.7 3.2 114.5% View Chart
Dividend Yield % 0.4 0.2 265.3%  

Financials

 AUROBINDO PHARMA   IPCA LABS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
IPCA LABS
Mar-17
AUROBINDO PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs895643 139.2%   
Low Rs622503 123.7%   
Sales per share (Unadj.) Rs254.6254.4 100.1%  
Earnings per share (Unadj.) Rs39.316.1 244.4%  
Cash flow per share (Unadj.) Rs46.629.8 156.4%  
Dividends per share (Unadj.) Rs2.501.00 250.0%  
Dividend yield (eoy) %0.30.2 188.8%  
Book value per share (Unadj.) Rs160.0194.6 82.2%  
Shares outstanding (eoy) m585.88126.20 464.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.02.3 132.3%   
Avg P/E ratio x19.335.7 54.2%  
P/CF ratio (eoy) x16.319.2 84.6%  
Price / Book Value ratio x4.72.9 161.0%  
Dividend payout %6.46.2 102.3%   
Avg Mkt Cap Rs m444,39072,300 614.6%   
No. of employees `00014.013.3 105.1%   
Total wages/salary Rs m17,6786,960 254.0%   
Avg. sales/employee Rs Th10,667.82,413.5 442.0%   
Avg. wages/employee Rs Th1,264.3523.2 241.7%   
Avg. net profit/employee Rs Th1,645.8152.4 1,079.6%   
INCOME DATA
Net Sales Rs m149,15732,106 464.6%  
Other income Rs m1,159226 513.5%   
Total revenues Rs m150,31632,332 464.9%   
Gross profit Rs m34,3434,448 772.1%  
Depreciation Rs m4,2761,730 247.3%   
Interest Rs m667241 277.1%   
Profit before tax Rs m30,5582,703 1,130.4%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,597675 1,125.1%   
Profit after tax Rs m23,0122,028 1,134.7%  
Gross profit margin %23.013.9 166.2%  
Effective tax rate %24.925.0 99.5%   
Net profit margin %15.46.3 244.2%  
BALANCE SHEET DATA
Current assets Rs m92,06217,340 530.9%   
Current liabilities Rs m66,2239,559 692.8%   
Net working cap to sales %17.324.2 71.5%  
Current ratio x1.41.8 76.6%  
Inventory Days Days106100 105.7%  
Debtors Days Days6857 119.0%  
Net fixed assets Rs m62,91920,779 302.8%   
Share capital Rs m586252 232.1%   
"Free" reserves Rs m93,13324,499 380.2%   
Net worth Rs m93,71924,553 381.7%   
Long term debt Rs m1,8143,517 51.6%   
Total assets Rs m162,49439,595 410.4%  
Interest coverage x46.812.2 382.8%   
Debt to equity ratio x00.1 13.5%  
Sales to assets ratio x0.90.8 113.2%   
Return on assets %14.65.7 254.3%  
Return on equity %24.68.3 297.3%  
Return on capital %32.710.5 312.1%  
Exports to sales %048.6 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA15,617 0.0%   
Imports (cif) Rs mNA4,571 0.0%   
Fx inflow Rs m75,83815,617 485.6%   
Fx outflow Rs m30,2245,828 518.6%   
Net fx Rs m45,6139,790 465.9%   
CASH FLOW
From Operations Rs m32,7862,764 1,186.1%  
From Investments Rs m-17,870-1,432 1,248.2%  
From Financial Activity Rs m-19,153-1,591 1,203.6%  
Net Cashflow Rs m-4,239-259 1,637.8%  

Share Holding

Indian Promoters % 54.1 45.9 117.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 11.4 69.7%  
FIIs % 27.7 25.3 109.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 17.4 58.6%  
Shareholders   69,601 36,892 188.7%  
Pledged promoter(s) holding % 8.6 2.1 400.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  ASTRAZENECA PHARMA  STRIDES SHASUN LTD  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Feb 16, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS